Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination with Paclitaxel and Cisplatin in First-Line Treatment of Advanced or Distant Metastatic Esophageal Squamous Cell Carcinoma
–5th approved indication by NMPA significantly expands eligible patient population SHANGHAI, China, May 16, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi